Biotechnology

Antibody
#Antibodies #argenx #Biology #Biotechnology #Drug development #Drug discovery #Muscles

argenx advances ARGX-119 in congenital myasthenic syndromes 

argenx has announced it will advance ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS). The decision follows the analysis of topline data from the Phase Ib study, in which ARGX-119 demonstrated a favourable safety and tolerability profile. “The… Read More

#News

Demyelination of neuron
#Antisense Oligonucleotides (ASOs) #Biotechnology #Rare disease #SynaptixBio

Biotech selects ASO drug candidate for incurable rare disease

Oxford-based SynaptixBio, which is developing a therapy for a rare, deadly, and currently incurable rare disease (H-ABC), says it has identified the drug it will take forward into clinical trials.  The drug, SB H-19642, is an antisense oligonucleotide (ASO), which is a short strand of synthetic DNA… Read More

#News

#Biotechnology #Cardiometabolic diseases #Drug development #Drug discovery #ICON #Pharmaceuticals #Survey

More efficient next-gen obesity clinical trials needed, says survey

ICON has released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe, focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. Read More

#News

#Biotechnology #Drug development #MoonLake #Nanobodies

Meet the researcher: Kristian Reich

DDW’s Megan Thomas looks at a day in the life of Professor Kristian Reich, Co-Founder and CSO of MoonLake.  MT: Can you tell us what you do and what you’re working on at the moment? KR: As Co-Founder and Chief Scientific Officer of MoonLake, an advancing biotechnology company without the… Read More

#Exclusive Content

USA flag
#Biotech hubs #Biotechnology #Market reporting #United States

Who should we be watching on the USA biotech stage?

Since the inauguration of President Trump in January, the United States has been constantly in the international news, but which US biotech companies are making headlines? Diana Spencer highlights five innovators. According to Cervicorn Consulting, the US biotechnology market size could reach around $1,470.82 billion by 20331  – though it… Read More

#Business & Investment #Exclusive Content #Market Reports

#Biotechnology #Europe #Fundraising

Europe’s largest biotech fund exceeds target with €165m

Sofinnova Biovelocita II has exceeded its target, successfully raising €165 million, with substantial backing from global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures.   The milestone marks a significant expansion of Sofinnova Partners’ biotech acceleration strategy, extending beyond Italy to include France, the UK, and Denmark, with ambitions… Read More

#Business & Investment #News

Monoclonal antibodies
#Antibodies #Biotechnology #Collaboration #Drug development #Drug discovery #Pierre Fabre Laboratories #RedRidge

Pharma/biotech biparatopic antibody collaboration agreed

Pierre Fabre Laboratories and RedRidge have announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody (BPA) drug candidates against multiple targets. In line with Pierre Fabre Laboratories’ innovation strategy, the partnership’s therapeutic focus will be on precision oncology as well as dermatology and rare diseases. Read More

#News

Scotland flag
#Bioprocessing #Biotechnology #Cell line development #Financing #uFraction8

Scottish biotech company secures £3.4m investment

uFraction8 has secured £3.4 ($4.2) million in new investment following the completion of a funding round led by Foresight Group.  Based in Falkirk with a fully-owned subsidiary in Poland, uFraction8’s microfiltration technology is designed to optimise cell and biomass production, offering a sustainable, energy-efficient alternative to traditional methods used in… Read More

#Business & Investment #News

#Biotechnology #Cancer research #Clinical trials #Drug development #Drug discovery #Drug targets #Opinion #Podcasts

The DDW Podcast: 2024 in review

As 2024 draws to a close, DDW’s Multimedia Editor and podcast host Megan Thomas rounds up all the free editorial episodes of the DDW podcast that were released. You can find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. DDW Highlights Innovative. Evolving. Developing. Busy. These… Read More

#News

Bispecific antibodies
#Alentis Therapeutics #Antibody drug conjugate (ADC) #Biotechnology #Collaboration #Financing #Novo Holdings #Solid tumours

Successful collaboration to advance ADCs for solid tumours 

Novo Holdings has co-led a $181.4 million Series D financing in Alentis Therapeutics, a clinical-stage biotechnology company, headquartered in Basel, Switzerland, which is developing a pipeline of Claudin-1 (CLDN1) targeted medicines.  This financing will enable Alentis to begin Phase I/II trials for two first-in-class ADCs: ALE.P02, which targets advanced or… Read More

#Business & Investment #News

Central nervous system
#Biotechnology #Nervgen #Nervous system disorders #Peptides #Spinal cord injury

Empowering the nervous system to repair itself

NervGen Pharma’s lead drug candidate, NVG-291, is being evaluated in an ongoing Phase Ib/IIa clinical trial in partnership with Shirley Ryan AbilityLab for patients with spinal cord injury (SCI). Unlike traditional approaches that manage symptoms, NVG-291 empowers the nervous system to repair itself. DDW’s Megan Thomas speaks with President and… Read More

#Exclusive Content #Opinion

#Biotechnology #Clinical trials #Drug development #Fibrotic disease

Calluna Pharma advances lead candidate for fibrotic diseases 

Biotechnology company Calluna Pharma has completed a Phase I clinical study for its lead product candidate targeting inflammatory and fibrotic diseases.  The company’s lead candidate, CAL101, was shown to have a favorable safety, pharmacokinetic (PK) and immunogenicity profile in the Phase I study.  CAL101 is… Read More

#News

United States of America
#Biotech hubs #Biotechnology #Market reporting #North America

North American biotech innovation: Who and where?

DDW’s Diana Spencer explores some of North America’s most important life science hubs and finds out the benefits of each unique ecosystem. The United States dominates the biotech sector in North America and globally, with an estimated value share of nearly 59% in 20211. According to Key Biotechnology Indicators collated… Read More

#Exclusive Content #Market Reports

#Biotechnology #Cardiometabolic diseases #Diabetes #Funding #Novo Nordisk #Pioneer Group

UK biotech Golden Ticket programme open for applications

Pioneer Group has teamed up with global healthcare company Novo Nordisk to launch a ‘Golden Ticket’ programme designed to help accelerate innovations in cardiometabolic health. The Golden Ticket programme is aimed at early-stage biotech companies focused on novel drug targets and transformational medicines in cardiometabolic diseases, rare blood and rare… Read More

#Business & Investment #News

GBP pound sterling funding
#Biopharmaceuticals #Biotechnology #Finance #Investment #mRNA #Novo Holdings #Oxford Nanopore Technologies

Investing in a new generation of molecular analysis technology 

Novo Holdings has announced a £5 million investment in Oxford Nanopore Technologies as part of an equity issue and intends to add to this investment over time, with further purchases in the secondary market, subject to availability and price (among other factors).  Oxford Nanopore has developed a new generation of… Read More

#Business & Investment #News

#Aardvark Therapeutics #Biotechnology #Drug discovery #Obesity

New podcast: A new paradigm of appetite and hunger

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Tien Lee, CEO… Read More

#News